vimarsana.com

Latest Breaking News On - Alphamab oncology - Page 1 : vimarsana.com

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp

United statesInnovent biologicsBristol myers squibbAkeso biopharmaDrugs under different phases of clinical developmentPharmaceuticals incDrug administrationUniversity collaborations licensing partnering analysisAlpine immune sciencesAkeso biopharma co ltdRoute of administrationBiocytogen pharmaceuticalsInhibitors companiesMolecular templates incAkeso incKey companies

Alphamab Oncology s KN046 Trial Misses Endpoint

Alphamab Oncology (HK:9966) has released an update. Alphamab Oncology has announced that the Phase III clinical trial of KN046 for treating advance.

Alphamab oncology

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016

SUZHOU, China, May 22, 2024 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I…

Hong kongChina national medical products administrationAlphamab oncologyMain boardHong kong stock exchangeBreakthrough designationChina national medical products

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesClaire beecroftChina national medical products administrationAmerican association for cancer research annual meetingAlphamab oncologyAmerican associationCancer research annual meetingPoster sectionMain boardHong kong stock exchangeBreakthrough designationChina national medical products

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights

SUZHOU, China, March 29, 2024 /PRNewswire/ Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and

Hong kongUnited statesJiangsu alphamabAsia pacificPharmaceuticals incChinese pharmaceutical innovative enterprisesChina national medical products administrationHong kong stock exchangeDrug administrationBellberry human research ethics committeeSociety for immunotherapy of cancerChinese pharmaceutical listed companiesEuropean society for medical oncology congressNature communicationsAmerican association for cancer researchAlphamab oncology

vimarsana © 2020. All Rights Reserved.